FDA panel unanimously backs Novartis' psoriasis drug
October 20, 2014 at 14:28 PM EDT
Oct 20 (Reuters) - An advisory panel to the U.S. Food and Drug Administration unanimously recommended the use of Novartis AG's anti-inflammation drug in patients with a type of psoriasis, paving the way for its approval.
